Novel prodrug with unique mechanism of action takes on the opioid crisis
Channel Medsystems has developed the Cerene® Cryotherapy Device to treat heavy menstrual bleeding.
Zenflow's technology relieves urinary blockage caused by enlarged prostate. The funding will accelerate progress to market.
Green Sun, a 2017 Rosenman Innovator, is developing a much-improved brace for children with scoliosis.
Science Magazine profiles Zymergen's AI/robotics technology for microbe engineering.
True North is a Mission Bay Capital portfolio company pursuing therapies that target the complement system to treat rare diseases.
Symic recently graduated from the QB3@953 incubator after several years' residence.
The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology.
eFFECTOR, in Mission Bay Capital's portfolio, is a leader in the development of selective translation regulators for the treatment of cancer.
eFT508 and avelumab are immunotherapies, designed to harness the body's own immune system in fighting cancer.
Atreca was an early portfolio company of QB3-affiliated Mission Bay Capital.
Atreca will apply its Immune Repertoire Capture® technology to generate sequences of native antibodies and TCRs from patients.
Sillajen is a former resident of the Mission Bay Innovation Center.
The partnership will develop intravitreal gene therapeutics for patients using 4DMT-proprietary AAV vectors.
Graphwear's wearable device employs an ultrathin layer of graphene in its sensor.
The partnership will yield an advanced information technology system for the forward engineering of microbial systems.
TeselaGen and Dow collaborate on a state-of-the-art biological design automation platform
The financing will help the company advance its Smart Growth Factor™ pipeline into the clinic.
Modus is a modular 'drop in' technology to monetize refinery offgas streams.
Not many synbio scientists have seen the results of their research onstage at Fashion Week in Paris.
The competition spotlights technology to convert corn into bio-renewable chemicals.
Lygos’ pilot collaboration is part of a two-year, $5 million, multi-company effort coordinated by the Agile BioFoundry.
Grifols, based in Spain, is set to acquire a 44% stake in GigaGen, a startup that discovers and develops pre-clinical biotherapeutics.
This will take Carmot's lead Type 2 diabetes drug through clinical proof of concept.
The firms will leverage Carmot’s Chemotype Evolution lead-identification technology.
The Award is sponsored by the Rosalind Franklin Society, whose goal is to support and showcase the careers of eminent women in science.
The Caribou CEO and co-founder spoke at TechCrunch Disrupt about the ethical and legal challenges of CRISPR technology.